Meribank Biotech , Ltd Accounts Payable

As of the most recent data (June 2026), 4724.TWO shows a accounts payable of $7.6M. That compares with $7.3M in the prior-year period — up 5.2% year over year. Scroll down for historical charts and peer comparison views.

Compared with the year-ago period, 4724.TWO's accounts payable is now $7.6M (was $7.3M) — a 5.2% year-over-year increase. Pairing that YoY change with peer averages gives a clearer picture of whether Meribank Biotech , Ltd is outperforming or lagging.

Tracking 4724.TWO's accounts payable over time shows whether Meribank Biotech , Ltd is scaling, shrinking, or reshaping that part of the business. The current reading is $7.6M That compares with $7.3M in the prior-year period — up 5.2% year over year. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.

Besides this accounts payable page, Stockcircle has Meribank Biotech , Ltd's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect accounts payable (currently $7.6M) with ownership activity and broader fundamentals.

Meribank Biotech , Ltd's accounts payable is $7.6M; compare it with other Healthcare names on the peer chart. Typical ranges vary by sub-industry, so always sanity-check against the closest competitors, not just the whole sector bucket.